Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;44(6):1267-1282.
doi: 10.1002/cbin.11340. Epub 2020 Mar 17.

Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies

Max London  1 , Eugenio Gallo  1
Affiliations
Review

Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies

Max London et al. Cell Biol Int. 2020 Jun.

Abstract

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of the family of tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to its autophosphorylation and subsequent activation of the signal transduction pathways involved in regulating cellular proliferation, differentiation, and survival. Accordingly, this receptor carries out both redundant and restricted functions in the germline development of mammals and in the maintenance of various adult tissues. Correspondingly, the loss of EGFR regulation results in many human diseases, with the most notable cancer. This receptor is overexpressed and/or mutated in multiple epithelial-derived tumors, and associated with poor prognosis and survival in cancer patients. Here, we discuss in detail the role of EGFR in specific epithelial-derived cancer pathologies; these include lung cancer, colorectal cancer, and squamous cell carcinomas. The development of multiple anticancer agents against EGFR diminished the progression and metastasis of tumors. Some of the most versatile therapeutic anti-EGFR agents include the monoclonal antibodies (mAbs), demonstrating success in clinical settings when used in combination with cytotoxic treatments, such as chemotherapy and/or radiation. We thus discuss the development and application of two of the most notable therapeutic mAbs, cetuximab, and panitumumab, currently utilized in various EGFR-related epithelial cancers.

Keywords: antibody therapeutics; cancer therapeutics; epidermal growth factor receptor; oncology; receptor tyrosine kinase.

PubMed Disclaimer

References

    1. Anderson JR, Davis RB (1986) Analysis of survival by tumor response. J Clin Oncol 4(1): 115-7. https://doi.org/10.1200/JCO.1986.4.1.115
    1. Ardinger HH, Buetow KH, Bell GI, Bardach J, VanDemark DR, Murray JC (1989) Association of genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. Am J Hum Genet 45(3): 348-53.
    1. Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, … Bardelli A (2016) MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 8(324): 324ra14. https://doi.org/10.1126/scitranslmed.aad5640
    1. Atkin WS, Morson BC, Cuzick J (1992) Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326(10): 658-62. https://doi.org/10.1056/NEJM199203053261002
    1. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, … Siena S (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3(6): 658-73. https://doi.org/10.1158/2159-8290.CD-12-0558

MeSH terms

Grants and funding

LinkOut - more resources